Literature DB >> 15294934

Cutting edge: differential roles for phosphoinositide 3-kinases, p110gamma and p110delta, in lymphocyte chemotaxis and homing.

Karin Reif1, Klaus Okkenhaug, Takehiko Sasaki, Joseph M Penninger, Bart Vanhaesebroeck, Jason G Cyster.   

Abstract

Despite the established role for PI3Ks in cell migration, the PI3Ks involved in lymphocyte chemotaxis are poorly defined. In this study, we report that p110gamma-deficient T cells, but not B cells, show reduced chemotactic responses to the lymphoid chemokines, CCL19, CCL21, and CXCL12. As B cell and T cell chemotactic responses were both sensitive to the general PI3K inhibitors, wortmannin (WMN) and LY294002, we explored whether B cell responses were affected in mice lacking p110delta, a major PI3K isoform in lymphocytes. B cells deficient in p110delta showed diminished chemotactic responses, especially to CXCL13. Adoptive transfer experiments with WMN-treated wild-type B cells and with p110delta-deficient B cells revealed diminished homing to Peyer's patches and splenic white pulp cords. WMN selectively inhibited CXCR5-dependent B cell homing to Peyer's patches. These observations establish that p110gamma and p110delta function in lymphocyte chemotaxis, and show differential roles for PI3K family members in B and T cell migration.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15294934     DOI: 10.4049/jimmunol.173.4.2236

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  79 in total

Review 1.  The emerging mechanisms of isoform-specific PI3K signalling.

Authors:  Bart Vanhaesebroeck; Julie Guillermet-Guibert; Mariona Graupera; Benoit Bilanges
Journal:  Nat Rev Mol Cell Biol       Date:  2010-04-09       Impact factor: 94.444

2.  The pan phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor SAR245409 (voxtalisib/XL765) blocks survival, adhesion and proliferation of primary chronic lymphocytic leukemia cells.

Authors:  R Thijssen; J Ter Burg; G G W van Bochove; M F M de Rooij; A Kuil; M H Jansen; T W Kuijpers; J W Baars; A Virone-Oddos; M Spaargaren; C Egile; M H J van Oers; E Eldering; M J Kersten; A P Kater
Journal:  Leukemia       Date:  2015-09-04       Impact factor: 11.528

Review 3.  Phosphatidylinositol-3,4,5-triphosphate and cellular signaling: implications for obesity and diabetes.

Authors:  Prasenjit Manna; Sushil K Jain
Journal:  Cell Physiol Biochem       Date:  2015-02-11

Review 4.  Lymphocyte cell motility: the twisting, turning tale of phosphoinositide 3-kinase.

Authors:  J S Oak; M P Matheu; I Parker; M D Cahalan; D A Fruman
Journal:  Biochem Soc Trans       Date:  2007-11       Impact factor: 5.407

5.  The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL.

Authors:  K Balakrishnan; M Peluso; M Fu; N Y Rosin; J A Burger; W G Wierda; M J Keating; K Faia; S O'Brien; J L Kutok; V Gandhi
Journal:  Leukemia       Date:  2015-04-28       Impact factor: 11.528

6.  Discovery of a Selective Phosphoinositide-3-Kinase (PI3K)-γ Inhibitor (IPI-549) as an Immuno-Oncology Clinical Candidate.

Authors:  Catherine A Evans; Tao Liu; André Lescarbeau; Somarajan J Nair; Louis Grenier; Johan A Pradeilles; Quentin Glenadel; Thomas Tibbitts; Ann M Rowley; Jonathan P DiNitto; Erin E Brophy; Erin L O'Hearn; Janid A Ali; David G Winkler; Stanley I Goldstein; Patrick O'Hearn; Christian M Martin; Jennifer G Hoyt; John R Soglia; Culver Cheung; Melissa M Pink; Jennifer L Proctor; Vito J Palombella; Martin R Tremblay; Alfredo C Castro
Journal:  ACS Med Chem Lett       Date:  2016-07-22       Impact factor: 4.345

7.  The spontaneously adhesive leukocyte function-associated antigen-1 (LFA-1) integrin in effector T cells mediates rapid actin- and calmodulin-dependent adhesion strengthening to ligand under shear flow.

Authors:  Hwee San Lek; Vicky L Morrison; Michael Conneely; Paul A Campbell; David McGloin; Stefanie Kliche; Colin Watts; Alan Prescott; Susanna C Fagerholm
Journal:  J Biol Chem       Date:  2013-04-12       Impact factor: 5.157

8.  PI3K p110δ inactivation antagonizes chronic lymphocytic leukemia and reverses T cell immune suppression.

Authors:  Shuai Dong; Bonnie K Harrington; Eileen Y Hu; Joseph T Greene; Amy M Lehman; Minh Tran; Ronni L Wasmuth; Meixiao Long; Natarajan Muthusamy; Jennifer R Brown; Amy J Johnson; John C Byrd
Journal:  J Clin Invest       Date:  2018-11-19       Impact factor: 14.808

9.  The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL.

Authors:  Ian W Flinn; Peter Hillmen; Marco Montillo; Zsolt Nagy; Árpád Illés; Gabriel Etienne; Julio Delgado; Bryone J Kuss; Constantine S Tam; Zoltán Gasztonyi; Fritz Offner; Scott Lunin; Francesco Bosch; Matthew S Davids; Nicole Lamanna; Ulrich Jaeger; Paolo Ghia; Florence Cymbalista; Craig A Portell; Alan P Skarbnik; Amanda F Cashen; David T Weaver; Virginia M Kelly; Barry Turnbull; Stephan Stilgenbauer
Journal:  Blood       Date:  2018-10-04       Impact factor: 22.113

10.  Involvement of phosphoinositide 3-kinase gamma in angiogenesis and healing of experimental myocardial infarction in mice.

Authors:  Mauro Siragusa; Rajesh Katare; Marco Meloni; Federico Damilano; Emilio Hirsch; Costanza Emanueli; Paolo Madeddu
Journal:  Circ Res       Date:  2010-01-07       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.